Compare ATNM & LGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATNM | LGL |
|---|---|---|
| Founded | 2000 | 1917 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8M | 40.9M |
| IPO Year | 2013 | N/A |
| Metric | ATNM | LGL |
|---|---|---|
| Price | $1.10 | $6.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 132.5K | 4.2K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $90,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $42.61 |
| Revenue Growth | ★ 11.11 | N/A |
| 52 Week Low | $0.95 | $5.45 |
| 52 Week High | $1.95 | $9.55 |
| Indicator | ATNM | LGL |
|---|---|---|
| Relative Strength Index (RSI) | 49.69 | 46.34 |
| Support Level | $1.02 | $6.90 |
| Resistance Level | $1.25 | $7.35 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 55.24 | 35.29 |
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.